Thomas Consolati, MD
Internal Medicine · Lee, MANPI 1326006362
Payments from drug & device makers
Across 252 payments — averaging $19.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$529
- GSK$526
- Neurocrine Biosciences, Inc.$504
- AstraZeneca$368
- Johnson & Johnson$302
- Merck$276
- plus $2K from 29 others
What the payments were for
- Food & beverage$4,931100%
- Education$230%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 32 | $529 |
| GSK | 45 | $526 |
| Neurocrine Biosciences, Inc. | 6 | $504 |
| AstraZeneca | 20 | $368 |
| Johnson & Johnson(2 entities) | 15 | $302 |
| Merck | 17 | $276 |
| Astellas Pharma US Inc | 13 | $262 |
| Lilly USA, LLC | 12 | $248 |
| AbbVie(2 entities) | 9 | $204 |
| Novo Nordisk | 10 | $183 |
| Otsuka America Pharmaceutical, Inc. | 7 | $167 |
| Abbott | 8 | $166 |
| Boehringer Ingelheim | 7 | $151 |
| Nestle Healthcare Nutrition Inc. | 6 | $143 |
| Sumitomo Pharma America, Inc. | 5 | $136 |
| E.r. Squibb & Sons, L.L.C. | 6 | $119 |
| Lundbeck LLC | 4 | $111 |
| Amgen | 7 | $109 |
| Novartis | 5 | $82 |
| Exact Sciences | 2 | $50 |
| Indivior Inc. | 1 | $33 |
| Seqirus USA Inc | 2 | $32 |
| UCB, Inc. | 1 | $30 |
| Avanir Pharmaceuticals, Inc. | 1 | $24 |
| Amarin Pharma, Inc. | 1 | $23 |
| Kowa Pharmaceuticals America, Inc. | 1 | $22 |
| Axsome Therapeutics, Inc. | 1 | $21 |
| Aimmune Therapeutics, Inc. | 1 | $21 |
| Daiichi Sankyo Inc. | 1 | $20 |
| Scpharmaceuticals Inc. | 1 | $19 |
| Mylan Specialty L.p. | 1 | $18 |
| Biogen | 1 | $17 |
| Sanofi Pasteur Inc. | 1 | $15 |
| Alkermes, Inc. | 1 | $14 |
| Corium, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INGREZZA$348
How this compares
$4,954 in reported general payments places this provider in the 90th percentile of 4,983 internal medicine providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 957 | $462,712 |
| Humira PenAdalimumab | 21 | $154,917 |
| XareltoRivaroxaban | 222 | $141,731 |
| JardianceEmpagliflozin | 152 | $97,541 |
| JanuviaSitagliptin Phosphate | 155 | $90,751 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 158 | $88,623 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 189 | $60,544 |
| FarxigaDapagliflozin Propanediol | 96 | $58,149 |
| OzempicSemaglutide | 39 | $58,002 |
| TrulicityDulaglutide | 35 | $50,392 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 87 | $41,912 |
| Lurasidone Hcl | 30 | $22,781 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 41 | $21,648 |
| MounjaroTirzepatide | 17 | $19,319 |
| CreonLipase/Protease/Amylase | 21 | $17,170 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Abrysvo | $529 | $523,2561,146 claims |
| Johnson & JohnsonXarelto | $302 | $141,731222 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $526 | $134,121251 claims |
| Boehringer IngelheimJardiance, Tradjenta | $151 | $105,700173 claims |
| MerckJanuvia | $276 | $90,751155 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $248 | $69,71052 claims |
| AstraZenecaFarxiga, Symbicort | $368 | $66,555121 claims |
| Novo NordiskOzempic | $183 | $58,00239 claims |
| AbbVieCreon, Linzess, Restasis, Synthroid | $204 | $37,972124 claims |
| Astellas Pharma US IncMyrbetriq | $262 | $15,15231 claims |
| NovartisEntresto | $82 | $12,76236 claims |
| UCB, Inc.Neupro | $30 | $10,72812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,983 internal medicine providers in Massachusetts.
Other internal medicine in Lee
- Noopur RajeBoston$19.9M
- Michael McCartneyNewburyport$17.6M
- Rebecca HeistBoston$17.4M
- Richard PlattBoston$13.5M
- Ryan CorcoranBoston$11.4M
- Joyce LiuCharlestown$10.3M
- Elizabeth LeeBoston$9.8M
- Adnan DahdulSpringfield$8.8M
- Ryan SullivanCambridge$8.5M
- Xiuning leBoston$7.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.